饥饿的科学与抗肥胖药物
摘要
加州大学旧金山分校（UCSF）生理学教授、霍华德·休斯医学研究所（HHMI）研究员 Zachary Knight 博士，详细阐述了调控饥饿、饱腹感及体重的神经与激素系统。本次对话涵盖大脑如何追踪体脂储量、食欲回路如何在第一口进食前就预测摄食量，以及以 Ozempic 为代表的新型 GLP-1 药物如何发挥减肥作用。本期节目还探讨了为何体重具有高度遗传性，以及为何在生物学层面维持减重成果如此困难。
核心要点
- 大脑拥有两套饥饿系统：短期系统（脑干）在 10–20 分钟的时间尺度上调节每餐进食量；长期系统（下丘脑）通过激素 leptin 在数周至数月的时间尺度上追踪体脂储量。
- AgRP 神经元在第一口进食前就能预测你将吃多少 —— 它们的活动在看到食物后数秒内即下降，基于食物的适口性、饥饿程度和食物获取难度，有效预测进餐量。
- 体重约 80% 由遗传决定，使其成为人类遗传决定程度最高的特征之一，与身高相当。环境变化会影响整个人群的分布，但遗传决定个体在该曲线上所处的位置。
- 瘦素抵抗（而非瘦素缺乏）是大多数肥胖者面临的主要问题 —— 类似于 insulin resistance 驱动 2 型糖尿病的机制。这正是为何注射瘦素作为肥胖治疗手段基本宣告失败。
- 每减轻约 2 磅体重，饥饿感每日约增加 100 卡路里 —— 使持续减重在生物学层面上极具挑战性，与意志力无关。
- GLP-1 药物（如 semaglutide/Ozempic、tirzepatide/Mounjaro）主要通过大脑和迷走神经（而非仅仅通过减缓胃排空）来抑制食欲。
- 蛋白质是受调控最为严格的宏量营养素 —— 身体会主动驱使摄入必需氨基酸。糖和脂肪的摄入调控相对宽松。
- 超加工食品促进过量摄入，即便与天然食品的适口性评分相当，原因可能在于其能量密度高、体积小，以及对正常营养素学习反馈回路的干扰。
- Sensory-specific satiety（感觉特异性饱腹感） —— 大脑对某种特定口味反复接触后降低食欲的倾向 —— 是较为简单、多样性较低的饮食自然减少热量摄入的机制之一。
详细笔记
饥饿调节的两套系统
大脑采用双系统架构来调节食物摄入：
- 脑干（短期）：在 10–20 分钟的时间尺度上控制每餐进食量。响应肠道信号，如胃扩张和激素 CCK（胆囊收缩素）。即便是仅保留脑干的”去大脑”大鼠，也能终止进食 —— 但无法在禁食状态下增加进食量。
- 下丘脑／前脑（长期）：在数天、数周乃至数月的时间尺度上追踪体脂储量。与脑干沟通，使短期进食行为与长期能量需求相匹配。
瘦素的作用
- Leptin（瘦素） 是一种仅由脂肪（脂肪）组织分泌的激素。
- 血液瘦素水平与体脂量呈线性正相关 —— 使其成为能量储量的实时指标。
- 瘦素受体几乎仅在大脑中表达，位于已知的食欲控制区域。
- 发现历程：ob 小鼠突变（在 Jackson Labs 发现）使瘦素生成缺失；db 突变则使瘦素受体失活。Doug Coleman 在 1960–70 年代通过联体共生实验揭示了一种循环因子，后被 Jeff Friedman 于 1994 年克隆鉴定为瘦素。
- 瘦素水平低的触发效应：饥饿感增加、能量消耗减少、体温下降、生育能力降低、自发活动减少。
- 瘦素疗法在肥胖患者中宣告失败，因为大多数肥胖者体内瘦素水平本已偏高 —— 他们的问题是瘦素抵抗，而非瘦素缺乏。
- 在显著减重后瘦素水平骤降、驱动体重反弹时，瘦素在体重维持方面未来仍可能具有应用价值。
AgRP 和 POMC 神经元
- AgRP neurons（AgRP 神经元）（刺鼠相关肽）：位于下丘脑基底部。数千个细胞对进食行为产生举足轻重的影响。
- 激活这些神经元会使饱食动物出现暴食行为。
- 抑制这些神经元会使动物完全停止进食，甚至需要安乐死。
- 表达瘦素受体 —— 受瘦素抑制（体脂高 → 饥饿驱动减弱）。
- POMC neurons（POMC 神经元）：AgRP 神经元的对应物，促进饱腹感。
- 投射至相同的下游脑区。
- 通过神经肽竞争 —— 一种作为激动剂，另一种作为拮抗剂，作用于下游的黑皮质素 4 受体（MC4R）。
- MC4R 突变是严重早发性肥胖最常见的单基因病因之一（约 10% 的重度肥胖者在该通路存在突变）。
AgRP 神经元的预测编码
Knight 博士实验室的研究揭示，AgRP 神经元并非在进食过程中逐渐下降活动 —— 它们在动物感知到食物后数秒内便急剧关闭，早于第一口进食。
- 这一餐前活动下降的幅度预测动物在此后 30 分钟内的进食量 —— 呈近似线性的相关关系。
- 这表明相关回路在执行预测建模：整合食物适口性、可获得性和当前饥饿状态等线索，预测热量摄入。
- 可能的功能：
- 启动 cephalic phase responses（头期反应，如胰岛素分泌、胃酸分泌、唾液分泌），为消化做好身体准备。
- 降低觅食驱动，使行为从寻食模式顺利过渡到进食模式。
- 在肠道热量信号到达之前，提前启动饱腹感进程。
遗传与肥胖
- 个体间约 80% 的体重差异由遗传决定 —— 是所有特征中遗传力估计值最高的之一。
- 自 1970 年代以来肥胖率的爆发式增长是环境因素所致（人类遗传学并未改变），但遗传决定了群体中哪些人对该环境最为易感。
- 关键表述：“遗传装填子弹；环境扣动扳机。”
- 大多数肥胖属于多基因性质 —— 全基因组关联研究（GWAS）已发现约 1,000 个与体重相关的基因，其中大多数在大脑中表达。
为何维持减重成果如此困难
- 每减轻约 2 磅，饥饿感每日约增加 100 千卡。
- 每减轻 1 千克，静息能量消耗约减少 30 千卡/天。
- 曾经肥胖并已显著减重的人，其能量消耗比从未肥胖的同等身高体重者低约 25%（“减重后肥胖”表型）。
- 这些代偿机制（主要由瘦素水平下降驱动）使持续减重在生物学上极具挑战性 —— 与行为努力无关。
GLP-1 与肥胖药物
- GLP-1（胰高血糖素样肽-1） 是一种肠促胰素激素 —— 它在口服摄入后放大血糖升高引起的胰岛素释放，与直接注射胰岛素相比，低血糖风险更低。
- 肠促胰素效应：口服葡萄糖引发的胰岛素分泌多于等剂量静脉注射葡萄糖 —— 信号来自肠道源性的胰腺胰岛素释放放大因子。
- 希拉毒蜥的关联：希拉毒蜥毒液中含有 exendin-4，这是一种半衰期远长于天然 GLP-1 的 GLP-1 类似物，由此推动了第一批 GLP-1 受体激动剂的开发。
- semaglutide（Ozempic、Wegovy） 和 tirzepatide（Mounjaro） 等药物通过 GLP-1 通路抑制食欲并促进减重。
- 这些药物被认为同时作用于迷走神经和脑内受体来减少食物摄入 —— 而非仅仅通过减缓胃排空发挥作用。
宏量营养素与食欲回路
- AgRP 神经元主要响应热量，而非宏量营养素种类 —— 等热量的脂肪、糖或蛋白质对其的抑制效果相当。
- 蛋白质
English Original 英文原文
The Science of Hunger & Medications to Combat Obesity
Summary
Dr. Zachary Knight, a professor of physiology at UCSF and HHMI investigator, explains the neural and hormonal systems that govern hunger, satiety, and body weight regulation. The conversation covers how the brain tracks body fat reserves, how appetite circuits predict food intake before the first bite, and how the new class of GLP-1 drugs like Ozempic work to reduce obesity. The episode also explores why body weight is highly heritable and why maintaining weight loss is so biologically difficult.
Key Takeaways
- The brain has two hunger systems: a short-term system (brain stem) that regulates meal size over 10–20 minutes, and a long-term system (hypothalamus) that tracks body fat over weeks to months via the hormone leptin.
- AgRP neurons predict how much you’ll eat before the first bite — their activity drops within seconds of seeing food, effectively forecasting meal size based on palatability, hunger level, and food accessibility.
- Body weight is approximately 80% heritable, making it one of the most genetically determined traits in humans — comparable to height. Environmental changes shift the entire population distribution, but genetics determines where an individual falls on that curve.
- Leptin resistance, not leptin deficiency, is the primary problem in most obese individuals — similar to how insulin resistance drives type 2 diabetes. This is why leptin injections largely failed as an obesity treatment.
- For every ~2 lbs of weight lost, hunger increases by approximately 100 calories/day — making sustained weight loss biologically challenging independent of willpower.
- GLP-1 drugs (e.g., semaglutide/Ozempic, tirzepatide/Mounjaro) suppress appetite primarily through the brain and vagus nerve, not just by slowing gastric emptying.
- Protein is the most strongly defended macronutrient — the body actively drives intake of essential amino acids. Sugar and fat intake are less tightly regulated.
- Ultra-processed foods promote overconsumption even when rated equally palatable to whole foods, likely due to energy density, reduced volume, and disruption of normal nutrient-learning feedback loops.
- Sensory-specific satiety — the brain’s tendency to reduce appetite for a specific flavor with repeated exposure — is one mechanism by which simpler, less varied diets naturally reduce caloric intake.
Detailed Notes
Two Systems for Hunger Regulation
The brain uses a dual-system architecture to regulate food intake:
- Brain stem (short-term): Controls meal size on a 10–20 minute timescale. Responds to gut signals like gastric stretch and hormones such as CCK (cholecystokinin). Even “decerebrate” rats with only a brain stem intact can terminate a meal — but cannot increase meal size in response to fasting.
- Hypothalamus / forebrain (long-term): Tracks body fat reserves over days, weeks, and months. Communicates with the brain stem to match short-term eating behavior to long-term energy needs.
The Role of Leptin
- Leptin is a hormone secreted exclusively by fat (adipose) tissue.
- Blood leptin levels rise and fall linearly with body fat mass — making it a real-time readout of energy reserves.
- Leptin receptors are expressed almost exclusively in the brain, in areas known to control appetite.
- Discovery: The ob mouse mutation (identified at Jackson Labs) abolished leptin production; the db mutation disabled the leptin receptor. Parabiosis experiments by Doug Coleman in the 1960s–70s revealed a circulating factor — later cloned by Jeff Friedman in 1994 as leptin.
- Low leptin triggers: increased hunger, decreased energy expenditure, decreased body temperature, decreased fertility, reduced spontaneous movement.
- Leptin therapy failed in obese patients because most obese individuals already have high leptin — they are leptin resistant, not leptin deficient.
- Leptin may still have future utility for weight maintenance after significant weight loss, when leptin levels plummet and drive weight regain.
AgRP and POMC Neurons
- AgRP neurons (agouti-related peptide): Located at the base of the hypothalamus. A few thousand cells with outsized influence on feeding.
- Stimulating them causes voracious eating in satiated animals.
- Silencing them causes animals to stop eating entirely, even to the point of requiring euthanasia.
- Express leptin receptors — inhibited by leptin (high fat → less hunger drive).
- POMC neurons: The counterpart to AgRP neurons. Promote satiety.
- Project to the same downstream brain regions.
- Compete via neuropeptides — one acts as an agonist, the other as an antagonist at the downstream melanocortin 4 receptor (MC4R).
- MC4R mutations are among the most common single-gene causes of severe early-onset obesity (~10% of severely obese individuals have mutations in this pathway).
Predictive Coding in AgRP Neurons
Research from Dr. Knight’s lab revealed that AgRP neurons do not gradually decline during eating — they shut off within seconds of the animal perceiving food, before the first bite.
- The magnitude of this pre-meal drop predicts how much the animal will eat in the next 30 minutes — a near-linear correlation.
- This suggests the circuits are performing predictive modeling: integrating cues like food palatability, accessibility, and current hunger state to anticipate caloric intake.
- Possible functions:
- Initiating cephalic phase responses (e.g., insulin secretion, gastric acid, saliva) to prepare the body for digestion.
- Reducing foraging drive to enable the transition from appetitive to consummatory behavior.
- Beginning the process of satiation before caloric signals from the gut arrive.
Genetics and Obesity
- ~80% of body weight variation between individuals is heritable — one of the highest heritability estimates of any trait.
- The explosion in obesity since the 1970s is environmental (human genetics haven’t changed), but genetics determines who within a population is most vulnerable to that environment.
- Key framing: “Genetics loads the gun; environment pulls the trigger.”
- Most obesity is polygenic — ~1,000 genes have been associated with body weight in GWAS studies, the majority expressed in the brain.
Why Maintaining Weight Loss Is Hard
- For every ~2 lbs lost, hunger increases by approximately 100 kcal/day.
- For every kilogram lost, resting energy expenditure decreases by approximately 30 kcal/day.
- People who were previously obese and have lost significant weight show ~25% lower energy expenditure than never-obese individuals of the same height and weight (“reduced obese” phenotype).
- These compensatory mechanisms (driven largely by falling leptin levels) make sustained weight loss biologically difficult — independent of behavioral effort.
GLP-1 and Obesity Drugs
- GLP-1 (glucagon-like peptide-1) is an incretin hormone — it amplifies insulin release in response to blood glucose after oral ingestion, reducing the risk of hypoglycemia compared to direct insulin.
- The incretin effect: oral glucose triggers more insulin than intravenous glucose of equivalent dose — signaling a gut-derived amplifier of pancreatic insulin release.
- The Gila monster connection: Gila monster venom contains exendin-4, a GLP-1 analog with a much longer half-life than native GLP-1, which led to the development of the first GLP-1 receptor agonists.
- Drugs like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) work through GLP-1 pathways to suppress appetite and promote weight loss.
- These drugs are thought to act on both the vagus nerve and brain receptors to reduce food intake — not solely through gastric slowing.
Macronutrients and Appetite Circuits
- AgRP neurons respond primarily to calories, not macronutrient type — equal-calorie doses of fat, sugar, or protein inhibit them equivalently.
- Protein